Toll Free: 1-888-928-9744
Published: Apr, 2014 | Pages:
50 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Idera Pharmaceuticals, Inc. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Idera Pharmaceuticals, Inc. - Product Pipeline Review - 2014', provides an overview of the Idera Pharmaceuticals, Inc.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Idera Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Idera Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Idera Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Idera Pharmaceuticals, Inc.'s pipeline products Reasons to buy - Evaluate Idera Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Idera Pharmaceuticals, Inc. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Idera Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Idera Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Idera Pharmaceuticals, Inc. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Idera Pharmaceuticals, Inc. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Idera Pharmaceuticals, Inc. Snapshot 5 Idera Pharmaceuticals, Inc. Overview 5 Key Information 5 Key Facts 5 Idera Pharmaceuticals, Inc. - Research and Development Overview 6 Key Therapeutic Areas 6 Idera Pharmaceuticals, Inc. - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Pipeline Products - Out-Licensed Products 11 Out-Licensed Products/Combination Treatment Modalities 12 Idera Pharmaceuticals, Inc. - Pipeline Products Glance 13 Idera Pharmaceuticals, Inc. - Clinical Stage Pipeline Products 13 Phase II Products/Combination Treatment Modalities 13 Phase I Products/Combination Treatment Modalities 14 Idera Pharmaceuticals, Inc. - Early Stage Pipeline Products 15 IND/CTA Filed Products/Combination Treatment Modalities 15 Preclinical Products/Combination Treatment Modalities 16 Idera Pharmaceuticals, Inc. - Drug Profiles 17 IMO-3100 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 IMO-8400 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 IMO-2055 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 GSO Compunds 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 IMO-4200 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 IMO-9200 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 TLR3 Agonist 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 Idera Pharmaceuticals, Inc. - Pipeline Analysis 28 Idera Pharmaceuticals, Inc. - Pipeline Products by Target 28 Idera Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 30 Idera Pharmaceuticals, Inc. - Pipeline Products by Molecule Type 31 Idera Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action 32 Idera Pharmaceuticals, Inc. - Recent Pipeline Updates 34 Idera Pharmaceuticals, Inc. - Dormant Projects 41 Idera Pharmaceuticals, Inc. - Discontinued Pipeline Products 42 Discontinued Pipeline Product Profiles 42 IMO-2055 42 IMO-2125 42 Idera Pharmaceuticals, Inc. - Company Statement 43 Idera Pharmaceuticals, Inc. - Locations And Subsidiaries 48 Head Office 48 Appendix 49 Methodology 49 Coverage 49 Secondary Research 49 Primary Research 49 Expert Panel Validation 49 Contact Us 50 Disclaimer 50
List of Tables Idera Pharmaceuticals, Inc., Key Information 5 Idera Pharmaceuticals, Inc., Key Facts 5 Idera Pharmaceuticals, Inc. - Pipeline by Indication, 2014 7 Idera Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2014 9 Idera Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2014 10 Idera Pharmaceuticals, Inc. - Out-Licensed Products in Pipeline, 2014 11 Idera Pharmaceuticals, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2014 12 Idera Pharmaceuticals, Inc. - Phase II, 2014 13 Idera Pharmaceuticals, Inc. - Phase I, 2014 14 Idera Pharmaceuticals, Inc. - IND/CTA Filed, 2014 15 Idera Pharmaceuticals, Inc. - Preclinical, 2014 16 Idera Pharmaceuticals, Inc. - Pipeline by Target, 2014 29 Idera Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2014 30 Idera Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2014 31 Idera Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2014 33 Idera Pharmaceuticals, Inc. - Recent Pipeline Updates, 2014 34 Idera Pharmaceuticals, Inc. - Dormant Developmental Projects,2014 41 Idera Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2014 42
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.